Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects

Rhinitis, Allergic, Seasonal Clinical Trial

Official title:

A Double-blind, Placebo-controlled, Randomized Single Dose Escalation Study and a Double-blind, Placebo-controlled, Randomised Parallel Group 14-days Once Daily Repeat Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of an Intranasal H1/H3 Dual Antagonist Compound in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00694993
• Other study ID #: HHI110157
• Status: Completed
• Phase: Phase 1
• First received: June 9, 2008
• Last updated: August 9, 2017
• Start date: December 17, 2007
• Est. completion date: May 26, 2008

Study information

• Verified date: August 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, placebo-controlled, randomized single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose study to investigate safety, tolerability and pharmacokinetics of an intranasal H1/H3 dual antagonist compound in healthy male subjects.

Description:

A double-blind, placebo-controlled, randomized single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose study to investigate safety, tolerability and pharmacokinetics of an intranasal H1/H3 dual antagonist compound in healthy male subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: May 26, 2008
• Est. primary completion date: May 26, 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Male subjects aged between 18 and 50 years inclusive.

• Body mass index within the range 19-29.9kg/m2 (inclusive), with weight range of 50 kg-100 kg (inclusive).

• Healthy (defined as individuals who are free from significant nasal, cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, malignancy, endocrine, neurological and psychiatric disease as determined by history, physical examination and screening investigations).

• Non-smoking status as verified by urinary cotinine levels below 500 ng/mL cotinine at the screening visit. This can include ex-smokers who have given up smoking for >1 year.

• Normal nasal examination as per Ear, Nose and Throat (ENT) assessment

• No significant ECG abnormalities and QTc (B) <450 msec.

• The subject is able and willing to give written informed consent to take part in the study and is available to complete all study measurements.

• Male subjects must agree to abstain from or use a condom during sexual intercourse with female partners of childbearing potential, to prevent either pregnancy in the female partner or the possible exposure of a pregnant or lactating female to the investigational product from the male subject's semen. In addition, female partners of male subjects must use a reliable contraceptive method listed in the protocol, or they must refrain from sexual intercourse from the first dose of study medication until 84 days after the last dose.

Exclusion Criteria:

• As a result of the medical interview, physical examination or screening investigations, the Investigator or appropriately qualified designee considers the subject unfit for the study.

• The subject has a history of drug or any other allergy, which, in the opinion of the Investigator or appropriately qualified designee, contraindicates their participation, including known or suspected personal history or family history of adverse reactions or hypersensitivity to anti histamines

• The subject has participated in a study with a new molecular entity during the previous 3 months or any other study during the previous 2 months.

• The subject regularly, or on average, drinks more than 21 units of alcohol a week or more than an average intake of 3 units per day.

• The subject is currently taking regular (or a course of) medication, prescribed (including all beta-agonists) or not (including over the counter medication or herbal remedies such as St Johns Wort). Paracetamol is an exception and will be permitted at daily doses of up to 4g following the first dose of investigational product.

• The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.

• The subject has tested positive for HIV.

• The subject has a positive drugs of abuse and alcohol test.

• Donation during the study would result in >500mL of blood being donated over a 56 day period

• Subjects with structural nasal abnormalities frequent nose bleeds, Perennial Allergic Rhinitis (PAR) and Seasonal Allergic Rhinitis (SAR) unless subjects with SAR are asymptomatic and it is outside of the pollen season

• Subjects who are unable to comply with study procedures

• Subject is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study

• Vulnerable subjects (eg. persons kept in detention)

Related Conditions & MeSH terms

• Rhinitis
• Rhinitis, Allergic
• Rhinitis, Allergic, Seasonal

Intervention

Drug:
• GSK1004723
GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
• Placebo
Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.

Locations

Country	Name	City	State
Germany	GSK Investigational Site	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Daley-Yates P, Ambery C, Sweeney L, Watson J, Oliver A, McQuade B. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158(1):84-98. doi: 10.1159/000329738. Epub 2011 Dec 29. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ECG monitoring during 24 hours after each dose in the single dose cohorts and on days 1 and 7 in the repeat dose cohorts.		during 24 hours after each dose in the single dose cohorts and on days 1 and 7 in the repeat dose cohorts
Primary	Heart rate and blood pressure changes over 24 hours after dosing in single and repeat dose cohorts		over 24 hours after dosing
Secondary	Blood drug levels for GSK1004723 following single and repeat intranasal dosing		Pre-dose, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
•   Results for study HHI110157 can be found on the GSK Clinical Study Register.